Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : OSI Pharmaceuticals (OSIP) - formerly Oncogene -- Ignore unavailable to you. Want to Upgrade?

To: StockMarketTruth who wrote (110)	6/20/2000 9:33:00 PM
From: Miljenko Zuanic	Respond to of 447

SMT, First let me say clearly that currently I am on side-line in regards the OSIP. I ride stock from $2.5-7 to $25-28. Insiders sell-of and concern about PFE cancer collaboration future (all programs not only EGFr) were main reason for my action. However, in your analysis (except TA which I do not understand and am not trying to understand because it can only confuse me and make things worse) you are wrong on many points: 1. <<Before the spike, OSIP had a market cap of approximately 400M. Biotech companies with a comparable level of ongoing research and sales had market caps of 250-350M, so OSIP was somewhat over priced at that time.>> Give me example that I can respond. 2. <<Phase II trials have not yet begun>> Two PII completed, third one ongoing. 3. <<Upon the completion of Phase III trials, there is no guarantee of FDA approval>> There is no guaranty that PIII will be run. OSI will first expand clinical development with combination PIIb trials. 4. <<That would put trial completion some time in 2003, which is in complete agreement with the company's stated plan.>> PFE and now OSIP development plan foresee drug marketing in 2003. However, I can comment on this because available clinical data (to me) are not sufficient for any projection. 5. <<Is a three-year-off maybe worth 200M to you? >> Depend on status of the other programs, business plan, collaboration, cash positions, technology value,... In short, OSIP is worth more than $200M. However, I do not base my investment on current worth, on what it may be (and will be) worth 3-5 years from now. That is the key for great investment return (not profit from trading). 6. I do not think that it is over-valued. Where will go from here, bits me. It is only guess. As I said I have my own reasons for be on side-line. It doesn't mean that I am right or wrong. When I have clear picture on some additional issue I will take appropriate action. OSIP continue to be (as it was) on my high priority list and close follow-up. Miljenko

To: StockMarketTruth who wrote (110)	6/20/2000 10:06:00 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 447

Oh, boy, the truth!!! How could we possibly have gone without, all this time??

To: StockMarketTruth who wrote (110)	7/25/2000 4:47:00 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 447

Conclusion: 3 day downward potential - 16 3 day upward potential - 24 risk reward -6.75/+1.25 (selling is roughly 5.5 times a better bet than buying) I forgot, TruthMan...... when did you predict that OSIP would hit a 52 week high, as it did today? Sure is a long way from $16.

To: StockMarketTruth who wrote (110)	8/3/2000 8:12:11 PM
From: scaram(o)uche	Respond to of 447

bag holders OSIP 41 1/4 +5 5/16 45 34 1/8 12497 +14.7% Poor guys/gals. And now there's a whole new crop brewing.

To: StockMarketTruth who wrote (110)	8/5/2000 10:09:40 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 447

Just in case you missed the latest, week-long interpretation of your wisdom........ OSI Pharmaceuticals Inc.. 42 3/4 45 4 1/16 +28.5%

To: StockMarketTruth who wrote (110)	9/25/2000 4:56:08 PM
From: scaram(o)uche	Respond to of 447

bag holders At $70/share....... this next crop is REALLY gonna be pissed.